Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoledronic acid - Axsome Therapeutics

Next Previous
Drug Profile

Zoledronic acid - Axsome Therapeutics

Alternative Names: AXS 02; Disodium (1-Hydroxy-2-(1H-Imidazol-1-yl)-1- Phosphonoethyl)Phosphonic Acid - Axsome Therapeutics; Disodium zoledronate tetrahydrate - Axsome Therapeutics; Oral zoledronate

Latest Information Update: 20 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ANTECIP BIOVENTURES
  • Developer Axsome Therapeutics
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • New Molecular Entity No

Highest Development Phases

  • Phase II Back pain
  • Discontinued Pain

Most Recent Events

  • 09 Mar 2021 Phase-II development for Back pain (chronic low back pain with modic changes) is ongoing in Finland (EudraCT2015-000751-25)
  • 11 Mar 2019 Axsome Therapeutics in-licenses patent portfolio from Antecip
  • 11 Mar 2019 Axsome Therapeutics has patent protection for zoledronic acid in USA and other countries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top